- Home
- FFC vs SLN Comparison
FFC vs SLN Comparison
Compare FFC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- SLN
- Stock Information
- Founded
- FFC 1983
- SLN 1994
- Country
- FFC United States
- SLN United Kingdom
- Employees
- FFC N/A
- SLN N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- SLN Health Care
- Exchange
- FFC Nasdaq
- SLN Nasdaq
- Market Cap
- FFC 741.9M
- SLN 281.0M
- IPO Year
- FFC N/A
- SLN N/A
- Fundamental
- Price
- FFC $16.56
- SLN $5.52
- Analyst Decision
- FFC
- SLN Buy
- Analyst Count
- FFC 0
- SLN 5
- Target Price
- FFC N/A
- SLN $32.60
- AVG Volume (30 Days)
- FFC 164.1K
- SLN 111.1K
- Earning Date
- FFC 01-01-0001
- SLN 08-14-2025
- Dividend Yield
- FFC 6.79%
- SLN N/A
- EPS Growth
- FFC N/A
- SLN N/A
- EPS
- FFC N/A
- SLN N/A
- Revenue
- FFC N/A
- SLN $27,701,000.00
- Revenue This Year
- FFC N/A
- SLN N/A
- Revenue Next Year
- FFC N/A
- SLN N/A
- P/E Ratio
- FFC N/A
- SLN N/A
- Revenue Growth
- FFC N/A
- SLN N/A
- 52 Week Low
- FFC $11.90
- SLN $1.97
- 52 Week High
- FFC $14.96
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- FFC 77.26
- SLN 51.96
- Support Level
- FFC $15.84
- SLN $5.33
- Resistance Level
- FFC $16.14
- SLN $6.05
- Average True Range (ATR)
- FFC 0.12
- SLN 0.44
- MACD
- FFC 0.04
- SLN -0.06
- Stochastic Oscillator
- FFC 96.00
- SLN 38.66
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.